Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib

Adel Kardosh, Nathaniel Soriano, Yen Ting Liu, Jasim Uddin, Nicos A. Petasis, Florence M. Hofman, Thomas C. Chen, Axel H. Schönthal

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib that lacks COX-2 inhibitory function. We and others have demonstrated that DMC, despite its inability to block COX-2, is able to potently mimic the antitumor effects of celecoxib in vitro and in vivo. In this current study, we investigated whether DMC would also be able to inhibit the growth of highly drug-resistant tumor cell variants. We focused on human multiple myeloma (MM) cells, as patients with MM frequently develop drug-resistant disease and ultimately succumb to death. Here we show that DMC (and celecoxib) inhibits the proliferation of various multiple myeloma cell lines, including several (multi) drug-resistant variants. Growth inhibition in drug-sensitive and drug-resistant cells is mediated via multiple effects, which include diminished signal transducer and activator of transcription 3 (STAT-3) and mitogen-activated protein (MAP) kinase kinase (MEK) activity, reduced expression of survivin and various cyclins, and is followed by apoptotic cell death. Thus, our study demonstrates that inhibition of proliferation and induction of apoptosis by DMC (and celecoxib) can be accomplished even in highly drug-resistant multiple myeloma cells, and that this effect is achieved via the blockage of multiple targets that are critical for multiple myeloma cell growth and survival.

Original languageEnglish (US)
Pages (from-to)4330-4338
Number of pages9
JournalBlood
Volume106
Issue number13
DOIs
StatePublished - Dec 15 2005
Externally publishedYes

Fingerprint

Celecoxib
Multiple Myeloma
Cells
Cell Line
Pharmaceutical Preparations
Cyclooxygenase 2
Growth
STAT3 Transcription Factor
Cyclins
Cyclooxygenase 2 Inhibitors
Mitogen-Activated Protein Kinase Kinases
Cell growth
Cell death

ASJC Scopus subject areas

  • Hematology

Cite this

Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. / Kardosh, Adel; Soriano, Nathaniel; Liu, Yen Ting; Uddin, Jasim; Petasis, Nicos A.; Hofman, Florence M.; Chen, Thomas C.; Schönthal, Axel H.

In: Blood, Vol. 106, No. 13, 15.12.2005, p. 4330-4338.

Research output: Contribution to journalArticle

Kardosh, Adel ; Soriano, Nathaniel ; Liu, Yen Ting ; Uddin, Jasim ; Petasis, Nicos A. ; Hofman, Florence M. ; Chen, Thomas C. ; Schönthal, Axel H. / Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. In: Blood. 2005 ; Vol. 106, No. 13. pp. 4330-4338.
@article{df9829b1918e4a95b473df2e59298b93,
title = "Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib",
abstract = "2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib that lacks COX-2 inhibitory function. We and others have demonstrated that DMC, despite its inability to block COX-2, is able to potently mimic the antitumor effects of celecoxib in vitro and in vivo. In this current study, we investigated whether DMC would also be able to inhibit the growth of highly drug-resistant tumor cell variants. We focused on human multiple myeloma (MM) cells, as patients with MM frequently develop drug-resistant disease and ultimately succumb to death. Here we show that DMC (and celecoxib) inhibits the proliferation of various multiple myeloma cell lines, including several (multi) drug-resistant variants. Growth inhibition in drug-sensitive and drug-resistant cells is mediated via multiple effects, which include diminished signal transducer and activator of transcription 3 (STAT-3) and mitogen-activated protein (MAP) kinase kinase (MEK) activity, reduced expression of survivin and various cyclins, and is followed by apoptotic cell death. Thus, our study demonstrates that inhibition of proliferation and induction of apoptosis by DMC (and celecoxib) can be accomplished even in highly drug-resistant multiple myeloma cells, and that this effect is achieved via the blockage of multiple targets that are critical for multiple myeloma cell growth and survival.",
author = "Adel Kardosh and Nathaniel Soriano and Liu, {Yen Ting} and Jasim Uddin and Petasis, {Nicos A.} and Hofman, {Florence M.} and Chen, {Thomas C.} and Sch{\"o}nthal, {Axel H.}",
year = "2005",
month = "12",
day = "15",
doi = "10.1182/blood-2005-07-2819",
language = "English (US)",
volume = "106",
pages = "4330--4338",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib

AU - Kardosh, Adel

AU - Soriano, Nathaniel

AU - Liu, Yen Ting

AU - Uddin, Jasim

AU - Petasis, Nicos A.

AU - Hofman, Florence M.

AU - Chen, Thomas C.

AU - Schönthal, Axel H.

PY - 2005/12/15

Y1 - 2005/12/15

N2 - 2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib that lacks COX-2 inhibitory function. We and others have demonstrated that DMC, despite its inability to block COX-2, is able to potently mimic the antitumor effects of celecoxib in vitro and in vivo. In this current study, we investigated whether DMC would also be able to inhibit the growth of highly drug-resistant tumor cell variants. We focused on human multiple myeloma (MM) cells, as patients with MM frequently develop drug-resistant disease and ultimately succumb to death. Here we show that DMC (and celecoxib) inhibits the proliferation of various multiple myeloma cell lines, including several (multi) drug-resistant variants. Growth inhibition in drug-sensitive and drug-resistant cells is mediated via multiple effects, which include diminished signal transducer and activator of transcription 3 (STAT-3) and mitogen-activated protein (MAP) kinase kinase (MEK) activity, reduced expression of survivin and various cyclins, and is followed by apoptotic cell death. Thus, our study demonstrates that inhibition of proliferation and induction of apoptosis by DMC (and celecoxib) can be accomplished even in highly drug-resistant multiple myeloma cells, and that this effect is achieved via the blockage of multiple targets that are critical for multiple myeloma cell growth and survival.

AB - 2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib that lacks COX-2 inhibitory function. We and others have demonstrated that DMC, despite its inability to block COX-2, is able to potently mimic the antitumor effects of celecoxib in vitro and in vivo. In this current study, we investigated whether DMC would also be able to inhibit the growth of highly drug-resistant tumor cell variants. We focused on human multiple myeloma (MM) cells, as patients with MM frequently develop drug-resistant disease and ultimately succumb to death. Here we show that DMC (and celecoxib) inhibits the proliferation of various multiple myeloma cell lines, including several (multi) drug-resistant variants. Growth inhibition in drug-sensitive and drug-resistant cells is mediated via multiple effects, which include diminished signal transducer and activator of transcription 3 (STAT-3) and mitogen-activated protein (MAP) kinase kinase (MEK) activity, reduced expression of survivin and various cyclins, and is followed by apoptotic cell death. Thus, our study demonstrates that inhibition of proliferation and induction of apoptosis by DMC (and celecoxib) can be accomplished even in highly drug-resistant multiple myeloma cells, and that this effect is achieved via the blockage of multiple targets that are critical for multiple myeloma cell growth and survival.

UR - http://www.scopus.com/inward/record.url?scp=28844442877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844442877&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-07-2819

DO - 10.1182/blood-2005-07-2819

M3 - Article

C2 - 16123214

AN - SCOPUS:28844442877

VL - 106

SP - 4330

EP - 4338

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -